

Sang Cheul Oh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2647123/publications.pdf>

Version: 2024-02-01

66
papers

4,243
citations

218592

26
h-index

123376

61
g-index

66
all docs

66
docs citations

66
times ranked

6248
citing authors

#	ARTICLE	IF	CITATIONS
1	Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study. <i>Gastric Cancer</i> , 2022, 25, 207-217.	2.7	9
2	Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 234-247.	5.1	268
3	Tumor Response and Symptom Palliation from RAINBOW , a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer. <i>Oncologist</i> , 2021, 26, e414-e424.	1.9	4
4	Prognostic implication of systemic inflammatory markers in young patients with resectable colorectal cancer. <i>Annals of Surgical Treatment and Research</i> , 2021, 100, 25.	0.4	7
5	Effects of the proximity of metastasis to the central vessels of the liver on surgical outcomes and survival in colorectal cancer with liver metastasis. <i>ANZ Journal of Surgery</i> , 2021, 91, E183-E189.	0.3	1
6	Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells. <i>Korean Journal of Internal Medicine</i> , 2021, 36, S196-S206.	0.7	9
7	Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. <i>Gastric Cancer</i> , 2021, 24, 946-958.	2.7	61
8	Cannabidiol Suppresses Angiogenesis and Stemness of Breast Cancer Cells by Downregulation of Hypoxia-Inducible Factors-1 α . <i>Cancers</i> , 2021, 13, 5667.	1.7	17
9	Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer. <i>Gastric Cancer</i> , 2020, 23, 143-153.	2.7	45
10	RUNX3 suppresses metastasis and stemness by inhibiting Hedgehog signaling in colorectal cancer. <i>Cell Death and Differentiation</i> , 2020, 27, 676-694.	5.0	43
11	Activating CCT2 triggers Gli-1 activation during hypoxic condition in colorectal cancer. <i>Oncogene</i> , 2020, 39, 136-150.	2.6	26
12	A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. <i>Gastric Cancer</i> , 2020, 23, 510-519.	2.7	155
13	Genipin increases oxaliplatin-induced cell death through autophagy in gastric cancer. <i>Journal of Cancer</i> , 2020, 11, 460-467.	1.2	16
14	S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1045-1056.	5.1	39
15	Korean red ginseng for cancer-related fatigue in colorectal cancer patients with chemotherapy: A randomised phase III trial. <i>European Journal of Cancer</i> , 2020, 130, 51-62.	1.3	34
16	Inflammatory markers as prognostic indicators in pancreatic cancer patients who underwent gemcitabine-based palliative chemotherapy. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 171-184.	0.7	10
17	A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First-line Therapy (KCSG ST10-01). <i>Oncologist</i> , 2019, 24, 18-e24.	1.9	25
18	Docosahexaenoic Acid Enhances Oxaliplatin-Induced Autophagic Cell Death via the ER Stress/Sesn2 Pathway in Colorectal Cancer. <i>Cancers</i> , 2019, 11, 982.	1.7	33

#	ARTICLE	IF	CITATIONS
19	Cannabidiol promotes apoptosis via regulation of XIAP/Smac in gastric cancer. <i>Cell Death and Disease</i> , 2019, 10, 846.	2.7	60
20	Korean Red Ginseng Extract Increases Apoptosis by Activation of the Noxa Pathway in Colorectal Cancer. <i>Nutrients</i> , 2019, 11, 2026.	1.7	5
21	Cannabidiol-induced apoptosis is mediated by activation of Noxa in human colorectal cancer cells. <i>Cancer Letters</i> , 2019, 447, 12-23.	3.2	106
22	Diallyl disulfide (DADS) boosts TRAIL-Mediated apoptosis in colorectal cancer cells by inhibiting Bcl-2. <i>Food and Chemical Toxicology</i> , 2019, 125, 354-360.	1.8	17
23	RUNX3 enhances TRAIL-induced apoptosis by upregulating DR5 in colorectal cancer. <i>Oncogene</i> , 2019, 38, 3903-3918.	2.6	30
24	Sonic hedgehog pathway activation is associated with cetuximab resistance and EPHB3 receptor induction in colorectal cancer. <i>Theranostics</i> , 2019, 9, 2235-2251.	4.6	28
25	Cannabidiol Enhances the Therapeutic Effects of TRAIL by Upregulating DR5 in Colorectal Cancer. <i>Cancers</i> , 2019, 11, 642.	1.7	22
26	Genipin Enhances the Therapeutic Effects of Oxaliplatin by Upregulating BIM in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 751-761.	1.9	14
27	Deficiency of 15-LOX-1 Induces Radioresistance through Downregulation of MacroH2A2 in Colorectal Cancer. <i>Cancers</i> , 2019, 11, 1776.	1.7	7
28	Codium fragile F2 sensitize colorectal cancer cells to TRAIL-induced apoptosis via c-FLIP ubiquitination. <i>Biochemical and Biophysical Research Communications</i> , 2019, 508, 1-8.	1.0	13
29	Genipin inhibits the invasion and migration of colon cancer cells by the suppression of HIF-1 α accumulation and VEGF expression. <i>Food and Chemical Toxicology</i> , 2018, 116, 70-76.	1.8	37
30	Prognostic significance of interim ¹⁸ F-fluorodeoxyglucose positron emission tomography-computed tomography volumetric parameters in metastatic or recurrent gastric cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, e302-e309.	0.7	4
31	Imatinib-induced apoptosis of gastric cancer cells is mediated by endoplasmic reticulum stress. <i>Oncology Reports</i> , 2018, 41, 1616-1626.	1.2	11
32	Anatomical distribution and detection rate of colorectal neoplasms according to age in the colonoscopic screening of a Korean population. <i>Annals of Surgical Treatment and Research</i> , 2018, 94, 36.	0.4	10
33	Upregulation of EphB3 in gastric cancer with acquired resistance to a FGFR inhibitor. <i>International Journal of Biochemistry and Cell Biology</i> , 2018, 102, 128-137.	1.2	19
34	PARK7 modulates autophagic proteolysis through binding to the N-terminally arginylated form of the molecular chaperone HSPA5. <i>Autophagy</i> , 2018, 14, 1870-1885.	4.3	23
35	Novel Systemic Therapies for Advanced Gastric Cancer. <i>Journal of Gastric Cancer</i> , 2018, 18, 1.	0.9	33
36	Overexpression of Romo1 is an unfavorable prognostic biomarker and a predictor of lymphatic metastasis in non-small cell lung cancer patients. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 4233-4246.	1.0	17

#	ARTICLE	IF	CITATIONS
37	Hedgehog signaling pathway as a potential target in the treatment of advanced gastric cancer. <i>Tumor Biology</i> , 2017, 39, 101042831769226.	0.8	17
38	Cyclopamine sensitizes TRAIL-resistant gastric cancer cells to TRAIL-induced apoptosis via endoplasmic reticulum stress-mediated increase of death receptor 5 and survivin degradation. <i>International Journal of Biochemistry and Cell Biology</i> , 2017, 89, 147-156.	1.2	20
39	Glioma-derived cancer stem cells are hypersensitive to proteasomal inhibition. <i>EMBO Reports</i> , 2017, 18, 150-168.	2.0	29
40	Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2017, 390, 2461-2471.	6.3	1,749
41	Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project. <i>Clinical Cancer Research</i> , 2017, 23, 4441-4449.	3.2	342
42	Long-term clinical outcomes of the single-incision technique for implantation of implantable venous access ports via the axillary vein. <i>Journal of Vascular Access</i> , 2017, 18, 345-351.	0.5	10
43	Reactive oxygen species modulator-1 (Romo1) predicts unfavorable prognosis in colorectal cancer patients. <i>PLoS ONE</i> , 2017, 12, e0176834.	1.1	26
44	Cardiac glycosides suppress the maintenance of stemness and malignancy via inhibiting HIF-1 α in human glioma stem cells. <i>Oncotarget</i> , 2017, 8, 40233-40245.	0.8	31
45	Ataxia telangiectasia mutated (ATM), could it be another useful biomarker for the successful treatment with the poly (ADP-ribose) polymerase inhibitor?. <i>Translational Gastroenterology and Hepatology</i> , 2016, 1, 3-3.	1.5	2
46	Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer. <i>BioMed Research International</i> , 2016, 2016, 1-14.	0.9	19
47	RUNX3 inhibits the metastasis and angiogenesis of colorectal cancer. <i>Oncology Reports</i> , 2016, 36, 2601-2608.	1.2	35
48	Development and Validation of a Six-Gene Recurrence Risk Score Assay for Gastric Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 6228-6235.	3.2	40
49	TRAIL-induced Caspase Activation Is a Prerequisite for Activation of the Endoplasmic Reticulum Stress-induced Signal Transduction Pathways. <i>Journal of Cellular Biochemistry</i> , 2016, 117, 1078-1091.	1.2	11
50	Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 581-589.	1.4	35
51	Iron chelator-induced apoptosis via the ER stress pathway in gastric cancer cells. <i>Tumor Biology</i> , 2016, 37, 9709-9719.	0.8	43
52	Metformin enhances TRAIL-induced apoptosis by Mcl-1 degradation via Mule in colorectal cancer cells. <i>Oncotarget</i> , 2016, 7, 59503-59518.	0.8	26
53	Changing strategies for target therapy in gastric cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 1179.	1.4	32
54	Shogaol overcomes TRAIL resistance in colon cancer cells via inhibiting of survivin. <i>Tumor Biology</i> , 2015, 36, 8819-8829.	0.8	18

#	ARTICLE	IF	CITATIONS
55	BMP-2 induces motility and invasiveness by promoting colon cancer stemness through STAT3 activation. <i>Tumor Biology</i> , 2015, 36, 9475-9486.	0.8	54
56	Significant Association of Oncogene YAP1 with Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients. <i>Clinical Cancer Research</i> , 2015, 21, 357-364.	3.2	127
57	Incidence and Risk Factors of Infectious Complications Related to Implantable Venous-Access Ports. <i>Korean Journal of Radiology</i> , 2014, 15, 494.	1.5	42
58	Hematogenous Metastasis of Ovarian Cancer: Rethinking Mode of Spread. <i>Cancer Cell</i> , 2014, 26, 77-91.	7.7	252
59	Update of Adjuvant Chemotherapy for Resected Gastric Cancer. <i>Journal of Gastric Cancer</i> , 2012, 12, 3.	0.9	17
60	Clinical Implication of Tumor Markers. <i>Korean Journal of Medicine</i> , 2012, 83, 197.	0.1	1
61	Metastasis to the Iliopsoas Muscle from Advanced Gastric Carcinoma: an Unusual Site of Metastasis. <i>Korean Journal of Medicine</i> , 2012, 82, 754.	0.1	0
62	Preoperative Chemotherapy in Advanced Stomach Cancer (Cons). <i>Journal of Gastric Cancer</i> , 2008, 8, 65.	0.9	1
63	Lack of association of fragile histidine triad (FHIT) polymorphisms with lung cancer in the Korean population. <i>Journal of Human Genetics</i> , 2007, 52, 668-674.	1.1	0
64	Treatment Outcomes and Toxicities of ABVD Combination Chemotherapy Compared with CVPP in Hodgkin's Disease. <i>The Korean Journal of Hematology</i> , 2007, 42, 335.	0.7	0
65	NK/T-Cell Lymphoma Associated with Epstein-Barr Virus in a Patient Infected with Human Immunodeficiency Virus: An Autopsy Case. <i>International Journal of Hematology</i> , 2004, 79, 480-483.	0.7	6
66	The Effect of Telomerase Antisense for the Differentiation of Embryonic Stem Cells to Hemopoietic Stem Cells. <i>Blood</i> , 2004, 104, 4201-4201.	0.6	0